Hims & Hers Health, Inc.
HIMSNew York Stock ExchangeFull coverage
Latest dossier
AI-generated
General research and analysis by Moatsight, not personalized investment advice. We show, you decide. Disclaimers
Q3 of fiscal year 2026 · Published Nov 10, 2026,
Hims & Hers sells prescription treatments and wellness products, mostly on subscription, to consumers who pay out of pocket through its app and website, with medicines shipped from its own pharmacies. In the third quarter of 2026 revenue grew 49% to $890.4 million, within the company's guidance, but about half of the growth came from the Eucalyptus acquisition, gross margin fell to 57% from 74% after the move from compounded to branded weight-loss drugs, and subscribers fell for the first time since at least the start of 2024. The company cut its 2026 Adjusted EBITDA guidance for the third time and reported a GAAP net loss of $33.0 million. Moatsight estimates revenue of about $3.8 billion and a GAAP net loss over the next four quarters, with the outlook resting on whether the margin of the new mix recovers and US demand returns once marketing does.
What you pay
| Figure | At the close | 5-yr median | 5-yr range |
|---|---|---|---|
| P/E | No value: no close yet | No value: no price history | |
| EV/Sales | No value: no close yet | No value: no price history | |
| EV/EBITDA | No value: no close yet | No value: no price history | |
| Price/FCF | No value: no close yet | No value: no price history | |
| Market cap | No value: no close yet | ||
| Net debt and other claims(enterprise value minus market cap) | No value: no close yet | ||
| Enterprise value | No value: no close yet |
How the business is doing
| Figure | Last 12 months | 1-year change1-year | Yearly, 3 years | 8 quarters |
|---|---|---|---|---|
| Revenue | $2.9B | +29.8%(better for the company) | +53.6% | Each quarter is listed in the row's details. |
| Diluted EPS | −$0.82 | n/m, not meaningful: now below zero | n/m, not meaningful: from zero or below | Each quarter is listed in the row's details. |
| Free cash flow | No value: not in the filings | No value: not in the filings | No value: not in the filings | No value: too few quarters |
| Gross margin | 63.8% | −11.2 pp(worse for the company) | −5.8 pp | Each quarter is listed in the row's details. |
| Operating margin | −8.1% | −13.3 pp(worse for the company) | −1.0 pp | Each quarter is listed in the row's details. |
| Net margin | −6.7% | −12.7 pp(worse for the company) | −0.7 pp | Each quarter is listed in the row's details. |
| Share count | 233.822M | No value: cannot be derived | +3.6% | Each quarter is listed in the row's details. |
How to read these figures
- Last 12 months: the latest four reported quarters added up, or a figure computed from them. The share count is its latest quarter's average.
- 1-year change: the last 12 months against the 12 months a year earlier. A margin's change is in percentage points (pp). On a Next 12 months row, it is Moatsight's estimate against the last 12 months.
- Yearly, 3 years: the yearly rate over the last 3 years, compounded. For a margin, its average change a year in percentage points.
- 8 quarters: the last 12 months at each of the latest 8 quarter ends, oldest on the left; the dot is the latest. The quarters themselves are on Financials.
- n/m: not meaningful, such as a rate of change from a loss.
- Color: a 1-year change in the gain color is better for the company, one in the loss color worse. The caret and the sign show which way it moved, and a row where lower is better says so in its details. Color judges the company's reported results, never its share price or Moatsight's estimates, and no other column is colored.
Price
No closing prices are stored for this listing yet.
Facts
- Exchange
- New York Stock Exchange · USD
- Kind
- Common stock
- Security
- Common Stock